Cassava Sciences Inc
NASDAQ:SAVA

  • LAST PRICE
    27.0600
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    26.8500/ 1
  • Ask / Lots
    27.4000/ 1
  • Open / Previous Close
    --- / 27.0600
  • Day Range
    ---
  • 52 Week Range
    8.7900
    42.2000
  • Volume
    11

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
SAVA
Cassava Sciences Inc
1.3B
-66.7x
---
ELVN
Enliven Therapeutics Inc
1.3B
-14.3x
---
KURA
Kura Oncology Inc
1.4B
-7.5x
---
PHVS
Pharvaris NV
1.1B
-8.3x
---
BCAX
Bicara Therapeutics Inc
1.2B
-19.2x
---
AVBP
Arrivent Biopharma Inc
1.2B
-13.9x
---
As of 2024-11-12

Company Information

Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on neuroscience. The Company's science is based on stabilizing, but not removing, a critical protein in the Alzheimer’s brain. Its scientific approach for the treatment of Alzheimer's disease seeks to simultaneously suppress both neurodegeneration and neuroinflammation. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease dementia. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimer’s brain. It is conducting two randomized placebo-controlled Phase III clinical trials of oral simufilam in patients with Alzheimer’s disease dementia. SavaDx, its lead investigational diagnostic product candidate, is a way to detect the presence of Alzheimer’s disease from a small sample of blood. SavaDx is a research-use only, non-safety related exploratory biomarker.

Contact Information

Headquarters
6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300AUSTIN, TX, United States 78731
Phone
512-501-2444
Fax
512-614-0414

Executives

Non-Executive Independent Chairman of the Board
Claude Nicaise
Executive Chairman of the Board
Richard Barry
Chief Financial Officer
Eric Schoen
Senior Vice President, General Counsel
R. Christopher Cook
Chief Medical Officer
James Kupiec

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$1.3B
Revenue (TTM)
$0.00
Shares Outstanding
48.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-0.60
EPS
$-0.41
Book Value
$3.25
P/E Ratio
-66.7x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.